ArticleACS omega2026
EPIC: A Machine-Learning Framework for Product-Dependent Behavior in β‑Glucosidases.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enzyme activity is often modulated by interactions with small molecules. As molecules that can accumulate in the vicinity of enzymes, products can directly influence enzymatic activity and give rise to diverse enzyme response behaviors. Despite this biological importance, relatively few computational tools explicitly model enzyme-product interactions and characterizing such interactions typically relies on resource intensive experimental assays, thereby limiting enzyme mining and engineering efforts. Here, we present Enzyme-Product Interaction Classifier and Curve Predictor (EPIC), a machine learning framework that predicts glucose-dependent relative activity profiles of β-glucosidases (BGLs) from information on amino acid sequence and assay conditions. We curated a dataset of 105 unique BGL sequences for glucose response prediction. We formulate this problem as both a classification task, assigning enzymes to different product response classes, and a regression task, modeling full relative activity-glucose concentration profiles. Across extensive cross-validation, EPIC demonstrates more balanced classification performance across all glucose-response classes than a naïve sequence-identity-based baseline, attaining an
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.